Oh MLH - Search Results

1

SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore.

Lau CS, Phua SK, Liang YL, Oh MLH, Aw TC. Lau CS, et al. Among authors: oh mlh. Vaccines (Basel). 2022 Feb 18;10(2):331. doi: 10.3390/vaccines10020331. Vaccines (Basel). 2022. PMID: 35214789 Free PMC article.

2

Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore.

Lau CS, Oh MLH, Phua SK, Liang YL, Li Y, Huo J, Huang Y, Zhang B, Xu S, Aw TC. Lau CS, et al. Among authors: oh mlh. Antibodies (Basel). 2022 May 27;11(2):38. doi: 10.3390/antib11020038. Antibodies (Basel). 2022. PMID: 35735357 Free PMC article.

3

210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine.

Lau CS, Oh MLH, Phua SK, Liang YL, Aw TC. Lau CS, et al. Among authors: oh mlh. Vaccines (Basel). 2022 Oct 12;10(10):1703. doi: 10.3390/vaccines10101703. Vaccines (Basel). 2022. PMID: 36298568 Free PMC article.

4

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster.

Lau CS, Thundyil J, Oh MLH, Phua SK, Liang YL, Li Y, Huo J, Huang Y, Zhang B, Xu S, Aw TC. Lau CS, et al. Among authors: oh mlh. Antibodies (Basel). 2022 Nov 8;11(4):70. doi: 10.3390/antib11040070. Antibodies (Basel). 2022. PMID: 36412836 Free PMC article.

5

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.

Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN, Low CY, Oh ML, Bouckenooghe A, Wartel TA, Crevat D. Leo YS, et al. Hum Vaccin Immunother. 2012 Sep;8(9):1259-71. doi: 10.4161/hv.21224. Epub 2012 Aug 16. Hum Vaccin Immunother. 2012. PMID: 22894958 Free PMC article. Clinical Trial.

6

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.

Park J, Archuleta S, Oh MH, Shek LP, Wang H, Bonaparte M, Frago C, Bouckenooghe A, Jantet-Blaudez F, Begue S, Gimenez-Fourage S, Pagnon A. Park J, et al. Hum Vaccin Immunother. 2021 Jul 3;17(7):2107-2116. doi: 10.1080/21645515.2020.1861875. Epub 2021 Feb 24. Hum Vaccin Immunother. 2021. PMID: 33626291 Free PMC article. Clinical Trial.

7

Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series.

Park J, Archuleta S, Oh MH, Shek LP, Jin J, Bonaparte M, Fargo C, Bouckenooghe A. Park J, et al. Hum Vaccin Immunother. 2020 Mar 3;16(3):523-529. doi: 10.1080/21645515.2019.1661204. Epub 2019 Nov 5. Hum Vaccin Immunother. 2020. PMID: 31464558 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7 results

Search Page